Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sofosbuvir Plus Ribavirin Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)

Next Previous
Trial Profile

Sofosbuvir Plus Ribavirin Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SWIFT-C

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 May 2018 Results assessing effect of sofosbuvir-based HCV treatment on plasma concentrations of tenofovir and cellular concentrations of tenofovir diphosphate, were published in the Journal of Antimicrobial Chemotherapy.
    • 24 Oct 2017 Results assessing 8 weeks of ledipasvir/sofosbuvir therapy in HIV-infected men with genotype 1 or 4 HCV infection, of the presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top